ECSP099779A - [4-(6-fluoro-7-metilamina-2,4-dioxo-1,4-dihidro-2h-quinazolina-3-ilo)-fenilo]-5-cloro tiofeno-2-ilo-sales de sulfonilurea, y las formas y métodos relacionados con el mismo - Google Patents

[4-(6-fluoro-7-metilamina-2,4-dioxo-1,4-dihidro-2h-quinazolina-3-ilo)-fenilo]-5-cloro tiofeno-2-ilo-sales de sulfonilurea, y las formas y métodos relacionados con el mismo

Info

Publication number
ECSP099779A
ECSP099779A EC2009009779A ECSP099779A ECSP099779A EC SP099779 A ECSP099779 A EC SP099779A EC 2009009779 A EC2009009779 A EC 2009009779A EC SP099779 A ECSP099779 A EC SP099779A EC SP099779 A ECSP099779 A EC SP099779A
Authority
EC
Ecuador
Prior art keywords
ilo
forms
sulfonylide
thiophen
quinazoline
Prior art date
Application number
EC2009009779A
Other languages
English (en)
Inventor
Anjali Pandey
Emma Sharp
Louisa Jane Quegan
Juan Wang
Matthew Nieder
Wolin Huang
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of ECSP099779A publication Critical patent/ECSP099779A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El presente invento presenta las sales novedosas de sulfonilurea de una sal de la fórmula (I), y sus formas polimorfas. Los compuestos en sus diferentes formas son inhibidores efectivos de los receptores ADP plaquetarios y que se pueden utilizar en sus diferentes composiciones farmacéuticas y que son especialmente efectivos para la prevención y/o tratamiento de las enfermedades cardiovasculares, especialmente en las enfermedades relacionadas con la trombosis. El invento también presenta un método para la preparación de dichos compuestos y formas y para la prevención o tratamiento de la trombosis y las enfermedades relacionadas con la trombosis en un mamífero, incluyendo el paso de la administración de una cantidad terapéuticamente efectiva de una sal de la fórmula (I) o una forma farmacéuticamente aceptable del mismo.
EC2009009779A 2007-05-02 2009-12-02 [4-(6-fluoro-7-metilamina-2,4-dioxo-1,4-dihidro-2h-quinazolina-3-ilo)-fenilo]-5-cloro tiofeno-2-ilo-sales de sulfonilurea, y las formas y métodos relacionados con el mismo ECSP099779A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92732807P 2007-05-02 2007-05-02

Publications (1)

Publication Number Publication Date
ECSP099779A true ECSP099779A (es) 2010-01-29

Family

ID=39651344

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009779A ECSP099779A (es) 2007-05-02 2009-12-02 [4-(6-fluoro-7-metilamina-2,4-dioxo-1,4-dihidro-2h-quinazolina-3-ilo)-fenilo]-5-cloro tiofeno-2-ilo-sales de sulfonilurea, y las formas y métodos relacionados con el mismo

Country Status (18)

Country Link
US (1) US20090042916A1 (es)
EP (1) EP2076510A2 (es)
JP (1) JP2010526105A (es)
KR (1) KR20100020455A (es)
CN (1) CN101720324A (es)
AU (1) AU2008247457A1 (es)
BR (1) BRPI0810800A2 (es)
CA (1) CA2686221A1 (es)
CO (1) CO6241155A2 (es)
EA (1) EA200901474A1 (es)
EC (1) ECSP099779A (es)
GT (1) GT200900282A (es)
IL (1) IL201829A0 (es)
MA (1) MA31397B1 (es)
MX (1) MX2009011836A (es)
TN (1) TN2009000452A1 (es)
WO (1) WO2008137809A2 (es)
ZA (1) ZA200907493B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101300013B (zh) * 2005-11-03 2012-11-28 博尔托拉制药公司 [4-(6-卤代-7-取代的-2,4-二氧代-1,4-二氢-2h-喹唑啉-3-基)-苯基]-5-氯-噻吩-2-基磺酰脲类及与其相关的形式和方法
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
WO2011006169A1 (en) 2009-07-10 2011-01-13 Portola Pharmaceuticals, Inc. Methods for diagnosis and treatment of thrombotic disorders mediated by cyp2c19*2
WO2011088152A1 (en) 2010-01-12 2011-07-21 Portola Pharmaceuticals, Inc. Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
US8987285B2 (en) * 2010-12-03 2015-03-24 Portola Pharmaceuticals, Inc. Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof
CN106777526B (zh) * 2016-11-25 2020-05-01 江苏大学 基于遗传算法的高温高压离心式叶轮多学科优化方法
US10933096B2 (en) 2017-12-22 2021-03-02 Aesthetics Biomedical, Inc. Biologic preserving composition and methods of use
WO2019126557A1 (en) 2017-12-22 2019-06-27 Aesthetics Biomedical, Inc. Biologic preserving composition and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847925A (en) * 1971-07-15 1974-11-12 En Nom Collectif Science Et Ci Benzenesulfonyl semicarbazides
DE3134780A1 (de) * 1981-09-02 1983-03-10 Hoechst Ag, 6000 Frankfurt "sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung"
US4720450A (en) * 1985-06-03 1988-01-19 Polaroid Corporation Thermal imaging method
US5314902A (en) * 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
EP1257550B1 (en) * 2000-02-04 2005-11-16 Portola Pharmaceuticals, Inc. Platelet adp receptor inhibitors
DE60144284D1 (de) * 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
WO2003059288A2 (en) * 2002-01-09 2003-07-24 Enzrel, Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
US20040242658A1 (en) * 2003-01-08 2004-12-02 Dr. Reddy's Laboratories Limited Amorphous form of rosiglitazone maleate and process for preparation thereof
PT1668002E (pt) * 2003-10-03 2009-11-25 Portola Pharm Inc 2,4-dioxo-3-quinazolinilarilsulfonilureias
CN101300013B (zh) * 2005-11-03 2012-11-28 博尔托拉制药公司 [4-(6-卤代-7-取代的-2,4-二氧代-1,4-二氢-2h-喹唑啉-3-基)-苯基]-5-氯-噻吩-2-基磺酰脲类及与其相关的形式和方法
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
EP2079464A2 (en) * 2007-05-02 2009-07-22 Portola Pharmaceuticals, Inc. Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Also Published As

Publication number Publication date
CA2686221A1 (en) 2008-11-13
WO2008137809A3 (en) 2009-01-22
AU2008247457A1 (en) 2008-11-13
BRPI0810800A2 (pt) 2014-10-29
CN101720324A (zh) 2010-06-02
KR20100020455A (ko) 2010-02-22
JP2010526105A (ja) 2010-07-29
MA31397B1 (fr) 2010-05-03
ZA200907493B (en) 2010-07-28
GT200900282A (es) 2010-05-21
WO2008137809A2 (en) 2008-11-13
MX2009011836A (es) 2010-05-20
US20090042916A1 (en) 2009-02-12
CO6241155A2 (es) 2011-01-20
TN2009000452A1 (en) 2011-03-31
EA200901474A1 (ru) 2010-04-30
IL201829A0 (en) 2010-06-16
EP2076510A2 (en) 2009-07-08

Similar Documents

Publication Publication Date Title
ECSP099779A (es) [4-(6-fluoro-7-metilamina-2,4-dioxo-1,4-dihidro-2h-quinazolina-3-ilo)-fenilo]-5-cloro tiofeno-2-ilo-sales de sulfonilurea, y las formas y métodos relacionados con el mismo
MX2020004932A (es) Compuestos utiles para inhibir a cdk7.
SG10201810154WA (en) Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
CY1118513T1 (el) Αναστολεις πρωτεϊνικης κινασης (παραλλαγες), χρηση αυτων στη θεραπεια ογκολογικων νοσων και μια φαρμακευτικη συνθεση βασισμενη σε αυτους
CO6290683A2 (es) Compuestos de pirido imidazolinas heterociclicas y sus composiciones como inhibidores de c-met
DOP2016000175A (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
MX2019007189A (es) Compuestos de amino-triazolopiridina y su uso en el trataniento del cancer.
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
DOP2010000343A (es) Derivados de quinolinas y quinoxalinas como inhibidores de cinasa de proteina tirosina
MX378867B (es) Inhibidores de la nep para el tratamiento de enfermedades caracterizadas por el ensanchamiento o remodelacion auricular.
MX2017004906A (es) Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma.
UY30477A1 (es) Derivados de [4,5']bipirimidinil-6,4´-diamina como inhibidores de cinasa de proteina
CO6741217A2 (es) Modulares de receptor de glucagón
UY34974A (es) Piridazina 1,4 disustituida, análogos de la misma y métodos para tratar las enfermedades relacionadas con deficiencia del smn
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
UY33921A (es) Oxazinopteridinas y oxazinoptiridinonas n-sustituidas
UY31046A1 (es) Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones
UY29322A1 (es) Inhibidores de cxcr2
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
WO2012135697A3 (en) Novel rho kinase inhibitors and methods of use
AR096543A1 (es) INHIBIDORES DE QUINASA PI3 d Y g SELECTIVOS DUALES
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
AR069508A1 (es) Derivados de quinolina 057; un proceso para su preparacion; una composicion farmaceutica; la preparacion de esta y el uso del compuesto para preparar un medicamento
UY33655A (es) Co-cristales y sales de inhibidores de ccr30